Controlled release of bone morphogenetic protein-2 enhances recruitment of osteogenic progenitor cells for de novo generation of bone tissue.
The objective of this study was to evaluate the cellular contribution to the phenomenon of de novo generation of bone tissue induced by the controlled release of bone morphogenetic protein-2 (BMP-2). Gelatin hydrogels (2 mg) incorporating BMP-2 (3 microg) with different water contents were subcutaneously implanted into the back of enhanced green fluorescent protein-chimeric mice to induce the ectopic de novo generation of bone tissue. The hydrogels incorporating BMP-2 could release BMP-2 at different time profiles. When evaluated radiologically and histologically, the ectopic de novo generation of bone tissue was induced by the controlled release of BMP-2 from the hydrogels around the hydrogel-implanted site. The relative percentage number of green fluorescent protein- to osteocalcin-positive cells recruited into the de novo generated bone tissue depended on the BMP-2 release profile. The higher the percentage, the stronger was the de novo generation of bone tissue. These findings indicate that bone marrow-derived osteoblast progenitor cells were recruited from the blood circulation by BMP-2 release and consequently contributed to the ectopic de novo generation of bone tissue. It is conceivable that the local concentration of BMP-2 modifies the recruitment profile of progenitor cells with an osteogenic potential around the release site of BMP-2, resulting in regulated volume of de novo generated bone tissue.
Kimura
Yu
Y
Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University , Kyoto, Japan .
Miyazaki
Nobuhiko
N
Hayashi
Naoki
N
Otsuru
Satoru
S
Tamai
Katsuto
K
Kaneda
Yasufumi
Y
Tabata
Yasuhiko
Y
D053687:Adult Stem Cells / Q000166:cytology* / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage* / Q000235:genetics; D001861:Bone Regeneration / Q000187:drug effects / Q000502:physiology; D002465:Cell Movement / Q000187:drug effects; D003692:Delayed-Action Preparations; D004343:Drug Implants; D005780:Gelatin; D049452:Green Fluorescent Proteins / Q000235:genetics; D006801:Humans; D020100:Hydrogels; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects* / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics; D023822:Tissue Engineering / Q000379:methods*
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D003692:Delayed-Action Preparations; D004343:Drug Implants; D020100:Hydrogels; D011994:Recombinant Proteins; D049452:Green Fluorescent Proteins; D005780:Gelatin